Sanofi reported 10 holdings worth US$534M as of Jun 30, 2026 (Form 13F)
As of Jun 30, 2026 · Filed Jul 28, 2026
Sanofi reported 10 holdings worth US$534M as of Jun 30, 2026. Largest: Meiragtx Holdings Plc, Inhibrx Biosciences, Inc. and Novavax, Inc. Filed Jul 28, 2026 (Form 13F).
- Holdings
- 10
- Value as reported
- US$534M
The filing in full
| Company | Shares | Value as reported | % of portfolio |
|---|---|---|---|
| Meiragtx Holdings Plc | 12.2M | US$165M | 30.9% |
| Inhibrx Biosciences, Inc. | 1.16M | US$110M | 20.5% |
| Novavax, Inc. | 6.88M | US$64.8M | 12.1% |
| Anaptysbio, Inc. | 822K | US$55.5M | 10.4% |
| Odyssey Therapeutics, Inc. | 1.99M | US$37.3M | 7.0% |
| Maplight Therapeutics, Inc. | 912K | US$32.7M | 6.1% |
| First Tracks Biotherapeutics, Inc. | 822K | US$16.5M | 3.1% |
| Immuneering Corporation | 2.71M | US$13.5M | 2.5% |
| Q32 Bio Inc. | 244K | US$3.11M | 0.58% |
| Eledon Pharmaceuticals, Inc. | 0 | US$0 | 0.00% |